Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
45.51
-1.67 (-3.54%)
Dec 27, 2024, 11:08 AM EST - Market open
Company Description
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Apogee Therapeutics, Inc.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 91 |
| CEO | Michael Henderson |
Contact Details
Address: 221 Crescent Street, Building 17 Waltham, Massachusetts 02453 United States | |
| Phone | 650 394 5230 |
| Website | apogeetherapeutics.com |
Stock Details
| Ticker Symbol | APGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001974640 |
| CUSIP Number | 03770N101 |
| ISIN Number | US03770N1019 |
| Employer ID | 93-4958665 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Henderson | Chief Executive Officer |
| Jane Pritchett Henderson | Chief Financial Officer |
| Noel Kurdi | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 144 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 4, 2024 | 144 | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |